1. Home
  2. MATV vs LBRX Comparison

MATV vs LBRX Comparison

Compare MATV & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$12.16

Market Cap

701.0M

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$22.80

Market Cap

563.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MATV
LBRX
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.0M
563.2M
IPO Year
1995
2025

Fundamental Metrics

Financial Performance
Metric
MATV
LBRX
Price
$12.16
$22.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$49.00
AVG Volume (30 Days)
306.7K
508.7K
Earning Date
02-18-2026
02-15-2026
Dividend Yield
3.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,982,500,000.00
N/A
Revenue This Year
$2.62
N/A
Revenue Next Year
$2.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.34
$13.36
52 Week High
$13.57
$23.15

Technical Indicators

Market Signals
Indicator
MATV
LBRX
Relative Strength Index (RSI) 47.87 N/A
Support Level $11.90 N/A
Resistance Level $12.45 N/A
Average True Range (ATR) 0.42 0.00
MACD -0.06 0.00
Stochastic Oscillator 22.73 0.00

Price Performance

Historical Comparison
MATV
LBRX

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: